WNK3 and cancer: Although these unique PR gene signatures highlight functional differences between modified PRs and their components, the overlap between these (predominantly proliferative) programs supports a strong role for PR in early tumor progression toward more aggressive cancer phenotypes, and in some cases, even highlights a phospho-PR gene signature associated with poor response to endocrine treatment [9].